GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Cash Flow for Dividends

Gyre Therapeutics (Gyre Therapeutics) Cash Flow for Dividends : $0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Cash Flow for Dividends?

Gyre Therapeutics's cash flow for dividends for the six months ended in Dec. 2023 was $0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Gyre Therapeutics Cash Flow for Dividends Historical Data

The historical data trend for Gyre Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Cash Flow for Dividends Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow for Dividends
- - -

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
Cash Flow for Dividends - - -

Gyre Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Cash Flow for Dividends
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023